Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Curative Repression of HIV-1
NCT07209267Phase 2Not yet recruiting
- Sponsor
- Emory University
- Start
- Oct 2026
- Primary completion
- Jan 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in human immunodeficiency virus infection (HIV), sponsored by Emory University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07209267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209267.